Expertise in
32
conditions

Dr. Joseph M. Tuscano

Oncology
Office
4501 X St Ste 3016, 
Sacramento, CA 
Offers Telehealth
Expertise in
32
conditions
Office
4501 X St Ste 3016, 
Sacramento, CA 

Overview

Joseph Tuscano is an Oncologist practicing medicine in Sacramento, California.

Dr. Tuscano is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Burkitt Lymphoma, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 88 peer reviewed articles and participating in 17 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Mercy Medical Center Redding
Marshall Medical Center
University Of California Davis Medical Center
Adventist Health And Rideout
Enloe Health

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 6 Less Insurance Carriers -

Locations

Office
4501 X St Ste 3016, Sacramento, CA 95817

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2026
Intervention Type: Biological, Procedure, Other
Study Drugs: Nivolumab, Talimogene Laherparevec
Study Phase: Phase 2
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2026
Intervention Type: Other, Biological
Study Drug: MEDI-570
Study Phase: Phase 1
A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma
A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Atezolizumab, Gemcitabine, Oxaliplatin, Rituximab
Study Phase: Phase 1
A Phase II Trial of the Combination of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
A Phase II Trial of the Combination of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 2
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: November 26, 2025
Intervention Type: Biological, Drug
Study Drugs: Blinatumomab, Lenalidomide
Study Phase: Phase 1
A Phase I/IB Pilot Study of CC-486 Combined With Lenalidomide and Obinutuzumab for Relapsed/Refractory Indolent B-Cell Lymphoma
A Phase I/IB Pilot Study of CC-486 Combined With Lenalidomide and Obinutuzumab for Relapsed/Refractory Indolent B-Cell Lymphoma
Enrollment Status: Completed
Publish Date: April 24, 2025
Intervention Type: Biological, Drug
Study Drugs: Lenalidomide, Obinutuzumab, Azacitidine
Study Phase: Phase 1
View 9 Less Clinical Trials

88 Total Publications

A Retrospective Study Evaluating the Efficacy of Fludarabine, Cytarabine, and Granulocyte Colony Stimulating Factor with/without Idarubicin Followed by Second Allogeneic Stem Cell Transplant in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia/Myelodysplastic Syndrome Following First Allogeneic Stem Cell Transplant.
A Retrospective Study Evaluating the Efficacy of Fludarabine, Cytarabine, and Granulocyte Colony Stimulating Factor with/without Idarubicin Followed by Second Allogeneic Stem Cell Transplant in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia/Myelodysplastic Syndrome Following First Allogeneic Stem Cell Transplant.
Journal: Transplantation and cellular therapy
Published: March 10, 2026
Similar Doctors
Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

UC Davis Comprehensive Cancer Center

2279 45th St, 
Sacramento, CA 
 (0.1 miles away)
916-734-5959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathan Riess is an Oncologist practicing medicine in Sacramento, California. Dr. Riess is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, Bone Marrow Aspiration, and Gastrostomy.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

UC Davis Comprehensive Cancer Center

2279 45th St, 
Sacramento, CA 
 (0.1 miles away)
916-734-5959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Primo Lara is an Oncologist practicing medicine in Sacramento, California. Dr. Lara is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Lung Cancer, Nephrectomy, and Orchiectomy.

Expertise in
13
conditions
Dr. Karen L. Kelly
Hematology | Oncology
Expertise in
13
conditions
Dr. Karen L. Kelly
Hematology | Oncology
Referral may be required

UC Davis Comprehensive Cancer Center

2279 45th St, 
Sacramento, CA 
 (0.1 miles away)
916-734-5959
Languages Spoken:
English

Karen Kelly is a Hematologist and an Oncologist practicing medicine in Sacramento, California. Dr. Kelly is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Joseph M. Tuscano

How do I make an appointment with Dr. Joseph M. Tuscano?

You can book an appointment with Dr. Joseph M. Tuscano by calling their office at 916-734-5959. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joseph M. Tuscano a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joseph M. Tuscano is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joseph M. Tuscano specialize in?

While Dr. Joseph M. Tuscano is a Oncology, they have specific expertise in Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Mantle Cell Lymphoma (MCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Joseph M. Tuscano participate in research or clinical trials?

Yes. Dr. Joseph M. Tuscano has published 88 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Joseph M. Tuscano's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joseph M. Tuscano accept my insurance?

Dr. Joseph M. Tuscano accepts most major insurance plans, including Anthem BCBS and Blue Shield of California. We recommend calling the office directly at 916-734-5959 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tuscano's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 18 Advanced Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile